ChemoCentryx Tech Stack

ChemoCentryx uses 8 technology products and services including Microsoft Word, ComplianceWire, Backbone.js, and more. Explore ChemoCentryx's tech stack below.

  • Microsoft Word
    Editors
  • ComplianceWire
    Education Management
  • Backbone.js
    Javascript Frameworks
  • Exhibit
    Javascript Graphics
  • Choices
    Javascript Libraries
  • Google
    Miscellaneous
  • JavaScript
    Programming Languages
  • New Relic
    Real User Monitoring

Media & News

ChemoCentryx's Email Address Formats

ChemoCentryx uses at least 4 format(s):
ChemoCentryx Email FormatsExamplePercentage
flast@chemocentryx.comJDoe@chemocentryx.com
25%
fmiddlelast@chemocentryx.comJMichaelDoe@chemocentryx.com
25%
firstlast@chemocentryx.comJohnDoe@chemocentryx.com
25%
flast@chemocentryx.comJDoe@chemocentryx.com
25%

Frequently Asked Questions

Where is ChemoCentryx's headquarters located?

Minus sign iconPlus sign icon
ChemoCentryx's main headquarters is located at 835 Industrial Road Suite 600 San Carlos, California 94070 US. The company has employees across 3 continents, including North AmericaAsiaAfrica.

What is ChemoCentryx's phone number?

Minus sign iconPlus sign icon
You can contact ChemoCentryx's main corporate office by phone at +1-650-210-2900. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ChemoCentryx's stock symbol?

Minus sign iconPlus sign icon
ChemoCentryx is a publicly traded company; the company's stock symbol is CCXI.

What is ChemoCentryx's official website and social media links?

Minus sign iconPlus sign icon
ChemoCentryx's official website is chemocentryx.com and has social profiles on LinkedIn.

How much revenue does ChemoCentryx generate?

Minus sign iconPlus sign icon
As of February 2024, ChemoCentryx's annual revenue reached $32M.

What is ChemoCentryx's SIC code NAICS code?

Minus sign iconPlus sign icon
ChemoCentryx's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ChemoCentryx have currently?

Minus sign iconPlus sign icon
As of February 2024, ChemoCentryx has approximately 69 employees across 3 continents, including North AmericaAsiaAfrica. Key team members include Vice President Preclinical And Small Molecule Pharmaceutical Development: A. P.Vice President Of Clinical Development And Translational Medicine: P. S.Head Of Pharmaceutical Development: B. Z.. Explore ChemoCentryx's employee directory with LeadIQ.

What industry does ChemoCentryx belong to?

Minus sign iconPlus sign icon
ChemoCentryx operates in the Biotechnology Research industry.

What technology does ChemoCentryx use?

Minus sign iconPlus sign icon
ChemoCentryx's tech stack includes Microsoft WordComplianceWireBackbone.jsExhibitChoicesGoogleJavaScriptNew Relic.

What is ChemoCentryx's email format?

Minus sign iconPlus sign icon
ChemoCentryx's email format typically follows the pattern of flast@chemocentryx.com. Find more ChemoCentryx email formats with LeadIQ.

How much funding has ChemoCentryx raised to date?

Minus sign iconPlus sign icon
As of February 2024, ChemoCentryx has raised $325M in funding. The last funding round occurred on Jun 10, 2020.

When was ChemoCentryx founded?

Minus sign iconPlus sign icon
ChemoCentryx was founded in 1997.
ChemoCentryx

ChemoCentryx

Biotechnology ResearchCalifornia, United States51-200 Employees

ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. 

Our goal is to change treatment paradigms in orphan and rare disease—specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor. 

We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

Section iconCompany Overview

Headquarters
835 Industrial Road Suite 600 San Carlos, California 94070 US
Phone number
+1-650-210-2900
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
CCXI
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1997
Employees
51-200

Section iconFunding & Financials

  • $325M

    ChemoCentryx has raised a total of $325M of funding over 8 rounds. Their latest funding round was raised on Jun 10, 2020.

  • $10M$50M

    ChemoCentryx's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $325M

    ChemoCentryx has raised a total of $325M of funding over 8 rounds. Their latest funding round was raised on Jun 10, 2020.

  • $10M$50M

    ChemoCentryx's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.